A phase II study of docetaxel and carboplatin with concurrent radiation therapy for locally advanced head and neck cancer

Objective: In this study we evaluate the clinical response and safety profile of a regimen of docetaxel. +. carboplatin concurrent with radiotherapy (RT) in locally advanced squamous cell carcinoma of head and neck (HNSCC). Methods: Between January 2006 and December 2008, we enrolled 38 patients (st...

Full description

Saved in:
Bibliographic Details
Main Authors: Imjai Chitapanarux, Vicharn Lorvidhaya, Ekasit Tharavichitkul, Somvilai Mayurasakorn, Pichit Sittitrai, Tienchai Pattarasakulchai, Rak Tananuwat, Chonticha Srivanitchapoom
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=78651295832&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/50274
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-50274
record_format dspace
spelling th-cmuir.6653943832-502742018-09-04T04:27:35Z A phase II study of docetaxel and carboplatin with concurrent radiation therapy for locally advanced head and neck cancer Imjai Chitapanarux Vicharn Lorvidhaya Ekasit Tharavichitkul Somvilai Mayurasakorn Pichit Sittitrai Tienchai Pattarasakulchai Rak Tananuwat Chonticha Srivanitchapoom Medicine Objective: In this study we evaluate the clinical response and safety profile of a regimen of docetaxel. +. carboplatin concurrent with radiotherapy (RT) in locally advanced squamous cell carcinoma of head and neck (HNSCC). Methods: Between January 2006 and December 2008, we enrolled 38 patients (stage IVA: 29 patients; stage III: 9 patients). Fourteen had oral cavity cancer (tongue 10, buccal mucosa 2, alveolar ridge 1, floor of mouth 1), 10 had oropharyngeal cancer (base of tongue 5, tonsil 5), 13 had laryngeal cancer, and 1 had maxillary sinus cancer. Patients received concurrent docetaxel 15mg/m21-h infusion plus carboplatin AUC of 2, 30-min infusion on days 1, 8, 15, 22, 29, and 36. RT began on day 1 of concurrent chemotherapy with 2cGy/fraction, 5 fractions/week (total dose: 66-70cGy). Tumor was assessed by CT scan 3 months post-completion of concurrent chemoradiotherapy. Results: Thirty-five patients were evaluated (2 refused to receive all treatments, 1 had serious adverse event [rash, wheezing] from docetaxel first dose). The primary study endpoint of clinical response was achieved in 26 (74.3%) patients, 6 (17.1%) had stable disease, and 3 (8.6%) had disease progression. The 2-year disease-free survival was 62.9% (CI: 45.85-79.95%). The 2-year overall survival was 64.1% (CI: 43.52-84.68%). The most common Grade 3 toxicities were mucositis, xerostomia and dysphagia (13.9% each) and dermatitis (11%). No Grade 4 toxicities were observed. Conclusion: In conclusion, this study with a limited number of patients, docetaxel. +. carboplatin concurrent with RT appears to show acceptable activity and is generally well tolerated in patients with locally advanced HNSCC. © 2010 Elsevier Ireland Ltd. 2018-09-04T04:27:35Z 2018-09-04T04:27:35Z 2011-02-01 Journal 03858146 2-s2.0-78651295832 10.1016/j.anl.2010.05.012 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=78651295832&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/50274
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Medicine
spellingShingle Medicine
Imjai Chitapanarux
Vicharn Lorvidhaya
Ekasit Tharavichitkul
Somvilai Mayurasakorn
Pichit Sittitrai
Tienchai Pattarasakulchai
Rak Tananuwat
Chonticha Srivanitchapoom
A phase II study of docetaxel and carboplatin with concurrent radiation therapy for locally advanced head and neck cancer
description Objective: In this study we evaluate the clinical response and safety profile of a regimen of docetaxel. +. carboplatin concurrent with radiotherapy (RT) in locally advanced squamous cell carcinoma of head and neck (HNSCC). Methods: Between January 2006 and December 2008, we enrolled 38 patients (stage IVA: 29 patients; stage III: 9 patients). Fourteen had oral cavity cancer (tongue 10, buccal mucosa 2, alveolar ridge 1, floor of mouth 1), 10 had oropharyngeal cancer (base of tongue 5, tonsil 5), 13 had laryngeal cancer, and 1 had maxillary sinus cancer. Patients received concurrent docetaxel 15mg/m21-h infusion plus carboplatin AUC of 2, 30-min infusion on days 1, 8, 15, 22, 29, and 36. RT began on day 1 of concurrent chemotherapy with 2cGy/fraction, 5 fractions/week (total dose: 66-70cGy). Tumor was assessed by CT scan 3 months post-completion of concurrent chemoradiotherapy. Results: Thirty-five patients were evaluated (2 refused to receive all treatments, 1 had serious adverse event [rash, wheezing] from docetaxel first dose). The primary study endpoint of clinical response was achieved in 26 (74.3%) patients, 6 (17.1%) had stable disease, and 3 (8.6%) had disease progression. The 2-year disease-free survival was 62.9% (CI: 45.85-79.95%). The 2-year overall survival was 64.1% (CI: 43.52-84.68%). The most common Grade 3 toxicities were mucositis, xerostomia and dysphagia (13.9% each) and dermatitis (11%). No Grade 4 toxicities were observed. Conclusion: In conclusion, this study with a limited number of patients, docetaxel. +. carboplatin concurrent with RT appears to show acceptable activity and is generally well tolerated in patients with locally advanced HNSCC. © 2010 Elsevier Ireland Ltd.
format Journal
author Imjai Chitapanarux
Vicharn Lorvidhaya
Ekasit Tharavichitkul
Somvilai Mayurasakorn
Pichit Sittitrai
Tienchai Pattarasakulchai
Rak Tananuwat
Chonticha Srivanitchapoom
author_facet Imjai Chitapanarux
Vicharn Lorvidhaya
Ekasit Tharavichitkul
Somvilai Mayurasakorn
Pichit Sittitrai
Tienchai Pattarasakulchai
Rak Tananuwat
Chonticha Srivanitchapoom
author_sort Imjai Chitapanarux
title A phase II study of docetaxel and carboplatin with concurrent radiation therapy for locally advanced head and neck cancer
title_short A phase II study of docetaxel and carboplatin with concurrent radiation therapy for locally advanced head and neck cancer
title_full A phase II study of docetaxel and carboplatin with concurrent radiation therapy for locally advanced head and neck cancer
title_fullStr A phase II study of docetaxel and carboplatin with concurrent radiation therapy for locally advanced head and neck cancer
title_full_unstemmed A phase II study of docetaxel and carboplatin with concurrent radiation therapy for locally advanced head and neck cancer
title_sort phase ii study of docetaxel and carboplatin with concurrent radiation therapy for locally advanced head and neck cancer
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=78651295832&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/50274
_version_ 1681423560181022720